Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial

B. J. Materson; B. A. Friedman; K. M. Hla; B. S. Neidorf; J. M. Gray; N. Glazer; S. Gross

doi:10.1177/106002808301700115

Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial

B. J. Materson, B. A. Friedman, K. M. Hla, B. S. Neidorf, J. M. Gray, N. Glazer, S. Gross

Medicine

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

Original language	English (US)
Pages (from-to)	51-54
Number of pages	4
Journal	Unknown Journal
Volume	17
Issue number	1
DOIs	https://doi.org/10.1177/106002808301700115
State	Published - Jan 1 1983

ASJC Scopus subject areas

Pharmacology, Toxicology and Pharmaceutics(all)
Pharmacology (medical)

Access to Document

10.1177/106002808301700115

Fingerprint Dive into the research topics of 'Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial'. Together they form a unique fingerprint.

Cite this

Materson, B. J., Friedman, B. A., Hla, K. M., Neidorf, B. S., Gray, J. M., Glazer, N., & Gross, S. (1983). Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial. Unknown Journal, 17(1), 51-54. https://doi.org/10.1177/106002808301700115

@article{2919f6ae238b4e779ddcd8f7528eeef6,

title = "Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial",

abstract = "Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.",

author = "Materson, {B. J.} and Friedman, {B. A.} and Hla, {K. M.} and Neidorf, {B. S.} and Gray, {J. M.} and N. Glazer and S. Gross",

year = "1983",

month = jan,

day = "1",

doi = "10.1177/106002808301700115",

language = "English (US)",

volume = "17",

pages = "51--54",

journal = "Scientific Computing and Instrumentation",

issn = "1078-8956",

publisher = "Springer Wien",

number = "1",

}

TY - JOUR

T1 - Slow-release oxprenolol compared with oxprenolol in hypertensive patients

T2 - A multicenter clinical trial

AU - Materson, B. J.

AU - Friedman, B. A.

AU - Hla, K. M.

AU - Neidorf, B. S.

AU - Gray, J. M.

AU - Glazer, N.

AU - Gross, S.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

AB - Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0020683196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020683196&partnerID=8YFLogxK

U2 - 10.1177/106002808301700115

DO - 10.1177/106002808301700115

M3 - Article

C2 - 6337801

AN - SCOPUS:0020683196

VL - 17

SP - 51

EP - 54

JO - Scientific Computing and Instrumentation

JF - Scientific Computing and Instrumentation

SN - 1078-8956

IS - 1

ER -